Company Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC.
It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa.
The company was founded in 2003 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 265 |
| CEO | Robert W. Duggan |
Contact Details
Address: 601 Brickell Key Drive, Suite 1000 Miami, Florida 33131 United States | |
| Phone | 305 203 2034 |
| Website | smmttx.com |
Stock Details
| Ticker Symbol | SMMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001599298 |
| CUSIP Number | 86627T108 |
| ISIN Number | US86627T1088 |
| Employer ID | 37-1979717 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-Chief Executive Officer, President and Director |
| Robert W. Duggan | Co-Chief Executive Officer and Executive Chairman |
| Manmeet Singh Soni CPA | Chief Operating Officer, Chief Financial Officer and Director |
| Prof. Kay Elizabeth Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Bhaskar Anand | Chief Accounting Officer |
| Nathan LiaBraaten | Senior Director of Investor Relations |
| Dave Gancarz | Chief Business and Strategy Officer |
| Dr. Fong Clow | Chief Biometrics Officer |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality and Pharmacovigilance Officer |
| Dr. Allen S. Yang M.D., Ph.D. | Head of Research & Development Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 23, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | 8-K | Current Report |
| Jan 29, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Nov 7, 2025 | 8-K | Current Report |
| Oct 29, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Oct 22, 2025 | 8-K | Current Report |
| Oct 20, 2025 | 10-Q | Quarterly Report |
| Oct 20, 2025 | 8-K | Current Report |